

Long-Term Treatment Outcomes of Patients Infected With Hepatitis B Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Adefovir Response

Clinical Infectious Diseases

61, 730-740

DOI: [10.1093/cid/civ396](https://doi.org/10.1093/cid/civ396)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures. <i>Clinical Drug Investigation</i> , 2015, 35, 843-850.	1.1	18
2	Newest Treatments for Hepatitis C: How Can We Manage Sustainability?. <i>Clinical Infectious Diseases</i> , 2015, 61, 1891-1892.	2.9	5
3	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: TableÂ1. <i>Gut</i> , 2015, 64, 1824-1833.	6.1	128
4	Treatment of Hepatitis C with First Generation Protease Inhibitors. <i>Advances in Pharmacoepidemiology & Drug Safety</i> , 2016, 05, .	0.1	0
6	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016, 30, 1039-1047.	1.0	42
7	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2016, 388, 1081-1088.	6.3	1,080
8	Clearance of Hepatitis C Virus After Fixedâ€Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 516-517.	0.9	7
9	Treatment of chronic hepatitis C in patients with cirrhosis. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 1.	1.0	12
10	Pharmacologic Therapies in Gastrointestinal Diseases. <i>Medical Clinics of North America</i> , 2016, 100, 827-850.	1.1	22
11	Hepatitis C following liver transplantation. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 346-352.	1.3	1
12	The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). <i>EBioMedicine</i> , 2016, 12, 189-195.	2.7	89
13	Management of HCV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 96-104.	0.5	5
14	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 839-845.	2.8	42
15	Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1164-1170.	1.9	17
16	Extrahepatic Manifestations of Chronic Hepatitis C Infection: a Review and Update. <i>Current Hepatology Reports</i> , 2016, 15, 150-157.	0.4	0
17	Followâ€Pup of patients with chronic hepatitis C and a sustained viral response. <i>Liver International</i> , 2016, 36, 67-71.	1.9	24
18	Is the benefit of treating patients with cirrhosis proven?. <i>Liver International</i> , 2016, 36, 21-27.	1.9	10
19	Reversion of disease manifestations after HCV eradication. <i>Journal of Hepatology</i> , 2016, 65, S95-S108.	1.8	143

#	ARTICLE	IF	CITATIONS
20	Management of the patient with SVR. <i>Journal of Hepatology</i> , 2016, 65, S120-S129.	1.8	54
21	Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3381-3383.	1.1	8
22	Review article: treatment as prevention “targeting people who inject drugs as a pathway towards hepatitis C eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 145-156.	1.9	11
23	End-Stage Liver Disease in HIV Infection: An Avoidable Burden?. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw537.	2.9	1
24	Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. <i>Infectious Diseases and Therapy</i> , 2016, 5, 491-508.	1.8	28
25	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 521-526.	1.5	24
26	Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 334.	1.3	38
27	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.4	13
28	Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. <i>Infectious Agents and Cancer</i> , 2016, 11, 24.	1.2	105
29	Is response to anti-HCV treatment predictive of mortality in HCV/HIV coinfecting people?. <i>Future Virology</i> , 2016, 11, 245-248.	0.9	0
30	Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S3-S11.	2.9	49
31	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016, 10, 424-435.	1.9	47
32	Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 21-36.	1.4	9
33	Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 683-694.	2.9	262
34	Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. <i>Current Infectious Disease Reports</i> , 2016, 18, 4.	1.3	8
35	Optimum combination therapy regimens for HIV/HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 299-309.	2.0	2
36	Buying cures versus renting health: Financing health care with consumer loans. <i>Science Translational Medicine</i> , 2016, 8, 327ps6.	5.8	31
37	Reply to “Surveillance for hepatocellular carcinoma: A tale of two countries” <i>Journal of Hepatology</i> , 2016, 64, 755-756.	1.8	2

#	ARTICLE	IF	CITATIONS
38	Eradication of hepatitis C virus and non-HIV-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. <i>Hepatology</i> , 2017, 66, 344-356.	3.6	49
39	Scaling up HCV treatment to achieve WHO targets by 2030. <i>Tropical Medicine and International Health</i> , 2017, 22, 372-374.	1.0	5
40	Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. <i>Journal of Medical Virology</i> , 2017, 89, 1304-1308.	2.5	0
41	Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy. <i>Annals of Pharmacotherapy</i> , 2017, 51, 307-314.	0.9	13
42	Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. <i>HIV Medicine</i> , 2017, 18, 685-689.	1.0	12
43	Treatment of Hepatitis C in Children. <i>Current Hepatology Reports</i> , 2017, 16, 18-25.	0.4	1
44	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis. <i>Transplantation</i> , 2017, 101, 916-923.	0.5	19
45	Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 139-149.	1.9	83
46	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, S1-S23.	0.5	29
47	High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfecting people who use drugs. <i>HIV Medicine</i> , 2017, 18, 647-654.	1.0	13
48	Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2017, 23, 1596-1600.	1.3	4
49	Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. <i>Transplantation Proceedings</i> , 2017, 49, 1409-1418.	0.3	5
50	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. <i>Value in Health</i> , 2017, 20, 1110-1120.	0.1	14
51	Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. <i>Clinical Infectious Diseases</i> , 2017, 65, 1006-1011.	2.9	32
52	Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). <i>Scientific Reports</i> , 2017, 7, 14421.	1.6	6
53	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.0	9
55	What is the impact of treatment for hepatitis C virus infection?. <i>Lancet, The</i> , 2017, 390, 107-109.	6.3	12
56	A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. <i>BMC Infectious Diseases</i> , 2017, 17, 140.	1.3	31

#	ARTICLE	IF	CITATIONS
57	The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172.	1.9	38
58	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. <i>Journal of Hepatology</i> , 2017, 66, 19-27.	1.8	44
59	Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 45-52.	1.4	20
60	Reinventing HCV Treatment: Past and Future Perspectives. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 287-296.	1.0	21
62	A Brief Update on the Treatment of Hepatitis C. , 0, , .		2
63	Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015. <i>BMC Infectious Diseases</i> , 2017, 17, 784.	1.3	7
64	Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?. <i>Clinical and Experimental Hepatology</i> , 2017, 4, 181-186.	0.6	21
65	Personalized Medicine for Hepatitis C Virus. , 2017, , 485-501.		1
66	Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. <i>Hepatology</i> , 2018, 68, 449-461.	3.6	84
67	Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City. <i>Journal of Public Health Management and Practice</i> , 2018, 24, 526-532.	0.7	11
68	Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1454-1462.	1.1	5
69	The impact of treatment of hepatitis C with <sc>DAA</sc>s on the occurrence of <sc>HCC</sc>. <i>Liver International</i> , 2018, 38, 139-145.	1.9	109
70	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.	2.9	21
71	Hepatitis C virus-infected kidney waitlist patients: Treat now or treat later?. <i>American Journal of Transplantation</i> , 2018, 18, 2443-2450.	2.6	17
72	Effectiveness and security of chronic hepatitis C treatment in coinfecting patients in real-world. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 608-616.	1.0	1
73	Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. <i>Medical Microbiology and Immunology</i> , 2018, 207, 183-194.	2.6	20
74	The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. <i>Hepatology</i> , 2018, 67, 1160-1162.	3.6	3
75	Non-healthcare costs of hepatitis C: a systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 19-30.	1.4	15

#	ARTICLE	IF	CITATIONS
76	Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997â€“2013): A nationwide population-based study in Spain. <i>European Journal of Internal Medicine</i> , 2018, 48, 69-74.	1.0	3
77	Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. <i>Hepatology</i> , 2018, 67, 847-857.	3.6	55
78	The benefits of hepatitis C virus cure: Every rose has thorns. <i>Journal of Viral Hepatitis</i> , 2018, 25, 320-328.	1.0	11
79	Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. <i>Aids</i> , 2018, 32, 337-346.	1.0	6
80	Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. <i>Scientific Reports</i> , 2018, 8, 12137.	1.6	4
81	The Impact of Direct-acting Antiviral Therapy for Hepatitis C on Hepatocellular Carcinoma Risk. <i>Current Hepatology Reports</i> , 2018, 17, 377-384.	0.4	14
82	Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 539-550.	0.7	4
83	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	1.6	22
84	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.	0.8	12
85	KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. <i>Kidney International Supplements</i> , 2018, 8, 91-165.	4.6	141
86	The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2013.	1.2	27
87	Consenso Mexicano para el Tratamiento de la Hepatitis C. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2018, 83, 275-324.	0.4	9
88	The removal of DAA restrictions in Europe â€“ One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018, 69, 1188-1196.	1.8	78
89	The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function. <i>Antiviral Therapy</i> , 2018, 23, 687-694.	0.6	9
90	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy154.	0.4	17
91	Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 624-632.	1.9	44
92	Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. <i>Journal of Hepatology</i> , 2018, 69, 966-968.	1.8	18
93	A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-Î± and ribavirin for chronic hepatitis C virus infection. <i>Virology Journal</i> , 2018, 15, 26.	1.4	6

#	ARTICLE	IF	CITATIONS
94	The Mexican consensus on the treatment of hepatitis C. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2018, 83, 275-324.	0.1	0
95	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. <i>International Journal of Cardiology</i> , 2018, 271, 296-300.	0.8	23
96	Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2829-2839.	1.1	13
97	Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. <i>Canadian Liver Journal</i> , 2018, 1, 78-105.	0.3	3
98	Expanding treatment for hepatitis C in Canada. <i>Cmaj</i> , 2018, 190, E667-E668.	0.9	1
99	Pegylated Interferon-Î± Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. <i>American Journal of the Medical Sciences</i> , 2018, 355, 566-572.	0.4	1
100	Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. <i>Journal of Hepatology</i> , 2019, 71, 1116-1125.	1.8	26
101	HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. <i>PLoS ONE</i> , 2019, 14, e0218388.	1.1	37
102	Antiviral Consideration for Transplantation Including Drug Resistance. , 2019, , 953-975.		2
103	Evidence-making hepatitis C cure: Towards a science that knows more carefully. <i>International Journal of Drug Policy</i> , 2019, 72, 40-46.	1.6	14
104	Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1257-1265.	1.0	32
105	Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. <i>JGH Open</i> , 2019, 3, 210-216.	0.7	7
106	Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. <i>Cells</i> , 2019, 8, 1249.	1.8	113
107	The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. <i>Liver International</i> , 2019, 39, 2261-2272.	1.9	58
108	Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA). <i>Scientific Reports</i> , 2019, 9, 12502.	1.6	1
109	JNÎ€4178 (ALÎ€335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C VirusÎ€Infected Patients Without Cirrhosis: OMEGAÎ€1. <i>Hepatology</i> , 2019, 69, 2349-2363.	3.6	6
110	Viral Hepatitis: Chronic Hepatitis C. , 2019, , .		1
111	Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada. <i>Canadian Journal of Public Health</i> , 2019, 110, 714-721.	1.1	9

#	ARTICLE	IF	CITATIONS
112	Management of HCV Infection in Decompensated Cirrhosis in the Transplantation Setting. , 2019, , 167-182.		0
113	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Digestive and Liver Disease, 2019, 51, 915-921.	0.4	13
114	Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review. Seminars in Liver Disease, 2019, 39, 341-353.	1.8	16
115	Benefits of hepatitis C cure with antivirals: why test and treat?. Future Microbiology, 2019, 14, 425-435.	1.0	3
116	Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Review of Anti-Infective Therapy, 2019, 17, 311-325.	2.0	16
117	The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implementation Science, 2019, 14, 26.	2.5	183
118	Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. Open Forum Infectious Diseases, 2019, 6, ofz099.	0.4	14
119	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	6.3	449
120	Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clinical Infectious Diseases, 2020, 71, 2354-2362.	2.9	23
121	A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. Journal of the Chinese Medical Association, 2019, 82, 186-190.	0.6	3
122	UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 2019, 7, 189-1030.	1.6	6
123	Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association, 2019, 82, 693-698.	0.6	7
124	HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. Aids, 2019, 33, 1167-1174.	1.0	15
125	Trends in cause-specific mortality in HIV“hepatitis C coinfection following hepatitis C treatment scale-up. Aids, 2019, 33, 1013-1022.	1.0	23
126	Chronic hepatitis C infection “ Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease, 2019, 51, 183-189.	0.4	11
127	Disparities in uptake of direct“acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver International, 2019, 39, 1400-1407.	1.9	59
128	Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS ONE, 2019, 14, e0208858.	1.1	4
129	Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Research, 2019, 259, 54-61.	1.1	5

#	ARTICLE	IF	CITATIONS
130	Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 143-148.	0.6	14
131	Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. <i>Hepatology</i> , 2019, 69, 487-497.	3.6	171
132	Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. <i>Critical Public Health</i> , 2019, 29, 260-273.	1.4	14
133	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>Hepatology</i> , 2020, 71, 1182-1197.	3.6	8
134	Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 933-940.	0.8	4
135	Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036913.	2.9	19
136	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 270-280.	1.0	27
137	Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England. <i>Journal of Viral Hepatitis</i> , 2020, 27, 20-27.	1.0	2
138	Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Hepatology</i> , 2020, 71, 686-721.	3.6	526
139	HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017. <i>Preventive Medicine</i> , 2021, 153, 106222.	1.6	7
140	Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 671-679.	1.0	41
141	Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. <i>Scientific Reports</i> , 2020, 10, 17820.	1.6	20
142	Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. <i>BMJ Open</i> , 2020, 10, e035224.	0.8	9
143	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. <i>Journal of Infectious Diseases</i> , 2020, 222, S745-S757.	1.9	9
144	Viral hepatitis in patients on hemodialysis. <i>Seminars in Dialysis</i> , 2020, 33, 254-262.	0.7	4
145	Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. <i>Journal of Infectious Diseases</i> , 2020, 222, 1334-1344.	1.9	7
146	Knowledge, Attitudes, and Behaviors Related to Hepatitis C Screening and Treatment among Health Care Providers in Washington, DC. <i>Journal of Community Health</i> , 2020, 45, 785-794.	1.9	6
147	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 253-263.	0.4	0

#	ARTICLE	IF	CITATIONS
148	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy—Results from the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2020, 27, 690-698.	1.0	24
149	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , 2020, 69, 2223-2231.	6.1	17
150	Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. <i>Renal Failure</i> , 2020, 42, 377-380.	0.8	0
151	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	1.9	69
152	Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. <i>Liver International</i> , 2021, 41, 33-47.	1.9	6
153	Residual risk of liver disease after hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2021, 74, 952-963.	1.8	22
154	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype 2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 334-345.	0.8	3
155	Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. <i>European Journal of Health Economics</i> , 2021, 22, 75-88.	1.4	4
156	Impact of liver stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 601-608.	1.4	16
157	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. <i>Drugs</i> , 2021, 81, 419-443.	4.9	12
158	Experience with regorafenib in the treatment of hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110169.	1.4	74
159	Emerging Management of Hepatitis C in Transplant. , 2021, , 951-969.		0
160	Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 43-50.	0.4	2
161	Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 739-754.	1.0	23
162	Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. <i>Medicina (Lithuania)</i> , 2021, 57, 210.	0.8	0
163	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 477-492.	1.8	15
164	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab325.	0.4	3
165	Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists. <i>Medical Care</i> , 2021, Publish Ahead of Print, 699-703.	1.1	1

#	ARTICLE	IF	CITATIONS
166	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. <i>World Journal of Gastroenterology</i> , 2021, 27, 2994-3009.	1.4	103
167	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	1.8	85
168	Trends in <sc>HCV</sc> treatment uptake, efficacy and impact on liver fibrosis in the Swiss <sc>HIV</sc> Cohort Study. <i>Liver International</i> , 2018, 38, 424-431.	1.9	22
169	Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. <i>F1000Research</i> , 2016, 5, 367.	0.8	11
170	Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. <i>PLoS ONE</i> , 2017, 12, e0179493.	1.1	14
171	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	1.1	37
172	Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-6.	0.7	17
173	Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 421-30.	0.1	2
174	Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. <i>Pathogens and Immunity</i> , 2018, 3, 149.	1.4	35
175	Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. <i>JMIR Research Protocols</i> , 2018, 7, e149.	0.5	9
176	Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	14
177	The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?. <i>Canadian Liver Journal</i> , 2018, 1, 4-13.	0.3	7
178	Impact of hepatitis C oral therapy in portal hypertension. <i>World Journal of Gastroenterology</i> , 2017, 23, 4669.	1.4	14
179	Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. <i>World Journal of Hepatology</i> , 2018, 10, 319-328.	0.8	18
180	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. <i>World Journal of Hepatology</i> , 2019, 11, 421-441.	0.8	12
181	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. <i>World Journal of Hepatology</i> , 2019, 11, 442-449.	0.8	5
182	Hepatitis C virus: A time for decisions. Who should be treated and when?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 33.	0.6	18
183	Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	13

#	ARTICLE	IF	CITATIONS
184	Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study. Iranian Red Crescent Medical Journal, 2017, 19, .	0.5	2
185	A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Research, 2016, 5, 2061.	0.8	1
187	Prognostic value of blood group specificity and IL-28B genotype for the assessment of liver fibrosis in patients with chronic genotype 1 hepatitis C, non-responders to the treatment with pegylated interferon α -2 and ribavirin. Klinicheskaia Meditsina, 2017, 95, 847-854.	0.2	0
188	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal of Virology, 2017, 6, 59-72.	1.3	7
189	Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepatitis Monthly, 2018, In Press, .	0.1	1
190	Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs. Translational Cancer Research, 2019, 8, S223-S232.	0.4	2
192	Emerging Management of Hepatitis C in Transplant. , 2020, , 1-20.		0
193	Major Advances in Hepatitis C Treatment but Not Hepatitis B. , 2020, , 103-129.		1
194	Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clinical Infectious Diseases, 2021, 72, 780-786.	2.9	7
196	Assessment of epidemiological situation of chronic hepatitis C in Samara Region. Medical Alphabet, 2020, , 52-54.	0.0	0
197	Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Global Health, 2020, 5, e003194.	2.0	3
198	The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations. Gastroenterology and Hepatology, 2016, 12, 1-11.	0.2	5
199	Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterology and Hepatology, 2017, 13, 587-595.	0.2	8
200	Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon- α 2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Iranian Journal of Public Health, 2018, 47, 1845-1853.	0.3	1
201	Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. Caspian Journal of Internal Medicine, 2020, 11, 41-46.	0.1	1
203	The Effect of Direct Acting Antivirals on Portal Hemodynamics in Patients with Post Hepatitis C Cirrhosis: Doppler Study. International Journal of Current Microbiology and Applied Sciences, 2020, 9, 3705-3714.	0.0	1
204	Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World Journal of Hepatology, 2022, 14, 62-79.	0.8	3
205	Evoluci3n de los pacientes con infecci3n cr3nica por hepatitis C con fibrosis avanzada o cirrosis curados con antivirales de acci3n directa. Seguimiento a largo plazo. Gastroenterolog3a Y Hepatolog3a, 2022, 45, 767-779.	0.2	3

#	ARTICLE	IF	CITATIONS
206	Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study. <i>Liver International</i> , 2022, 42, 1278-1286.	1.9	3
207	Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals. <i>Annals of Saudi Medicine</i> , 2022, 42, 89-95.	0.5	1
208	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 396-404.	0.9	1
209	HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	1.0	4
211	Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	1
212	Higher Mortality in People Living with HIV after Cure of Hepatitis C by Direct-Acting Antivirals Compared to Those Without Hepatitis C: Results from the ANRS CO4 FHDH Cohort. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
213	Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up. <i>Gastroenterology & Hepatology (English Edition)</i> , 2022, 45, 767-779.	0.0	1
214	KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. <i>Kidney International</i> , 2022, 102, S129-S205.	2.6	10
215	The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. <i>Aids</i> , 2023, 37, 91-103.	1.0	1
216	Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain. <i>PLoS ONE</i> , 2022, 17, e0278544.	1.1	0
217	Risk factors for loss to follow-up after the start of direct-acting antiviral treatment for hepatitis C virus infection. <i>JGH Open</i> , 2023, 7, 98-104.	0.7	0
218	Current Landscape of HCV Therapeutics. , 2023, , 142-174.		0
219	Liver diseases: Perspective from the Philippines. <i>Annals of Hepatology</i> , 2023, 28, 101085.	0.6	4
220	Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2023, 32, 31-42.	0.2	0